Barclays analyst Luke Sergott raised the firm’s price target on Sotera Health (SHC) to $18 from $17 and keeps an Overweight rating on the shares. The firm says “no news is good news” on litigation as the California case count holds steady at 18.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC: